Benjamin Oakes’ Scribe Therapeutics is developing specialized Crispr proteins for multiple diseases–and it’s got deals with Big Pharma potentially worth over $4 billion
‘Focused Research Organizations’ aim to provide useful tools and information to the scientific community in areas that currently aren’t being served by academia or business.